CO5611107A2 - Sales de valsartan - Google Patents

Sales de valsartan

Info

Publication number
CO5611107A2
CO5611107A2 CO04086386A CO04086386A CO5611107A2 CO 5611107 A2 CO5611107 A2 CO 5611107A2 CO 04086386 A CO04086386 A CO 04086386A CO 04086386 A CO04086386 A CO 04086386A CO 5611107 A2 CO5611107 A2 CO 5611107A2
Authority
CO
Colombia
Prior art keywords
valsartan
salt
salts
tetrahydrate
polymorphs
Prior art date
Application number
CO04086386A
Other languages
English (en)
Spanish (es)
Inventor
Marti Erwin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5611107A2 publication Critical patent/CO5611107A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CO04086386A 2002-02-04 2004-09-02 Sales de valsartan CO5611107A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35419902P 2002-02-04 2002-02-04

Publications (1)

Publication Number Publication Date
CO5611107A2 true CO5611107A2 (es) 2006-02-28

Family

ID=27734333

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04086386A CO5611107A2 (es) 2002-02-04 2004-09-02 Sales de valsartan

Country Status (17)

Country Link
US (3) US6869970B2 (cg-RX-API-DMAC7.html)
EP (1) EP1474402A1 (cg-RX-API-DMAC7.html)
JP (2) JP4895475B2 (cg-RX-API-DMAC7.html)
KR (3) KR20040081178A (cg-RX-API-DMAC7.html)
CN (2) CN100548993C (cg-RX-API-DMAC7.html)
AU (1) AU2003214054B2 (cg-RX-API-DMAC7.html)
BR (1) BR0307442A (cg-RX-API-DMAC7.html)
CA (2) CA2776902A1 (cg-RX-API-DMAC7.html)
CO (1) CO5611107A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP045221A (cg-RX-API-DMAC7.html)
MX (1) MXPA04007525A (cg-RX-API-DMAC7.html)
NO (1) NO328155B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ534560A (cg-RX-API-DMAC7.html)
PL (1) PL370481A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004126862A (cg-RX-API-DMAC7.html)
WO (1) WO2003066606A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405698B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
ES2315510T3 (es) * 2002-06-13 2009-04-01 Novartis Ag Sales de calcio de estatinas derivadas del indol.
DE602004013405T2 (de) * 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
MXPA05012299A (es) * 2003-05-16 2006-01-30 Novartis Ag Composicion farmaceutica que comprende valsartan.
CA2544747A1 (en) * 2003-11-14 2005-05-26 Novartis Ag At1-receptor antagonists for treating nephrotic syndrome
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
ES2277199T3 (es) * 2004-04-15 2007-07-01 Helm Ag Procedimiento para la preparacion de adsorbatos de valsartan pulverulentos de flujo libre.
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
EP1806137A4 (en) * 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20090304797A1 (en) * 2006-06-23 2009-12-10 Tarur Venkatasubramanian Radha Process for the Preparation of Micronized Valsartan
PE20120542A1 (es) 2006-06-27 2012-05-14 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
PE20080907A1 (es) * 2006-08-31 2008-08-22 Novartis Ag Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
ES2336755B1 (es) * 2008-10-07 2011-01-21 Activery Biotech, S.L. Procedimiento para la preparacion de combinaciones de valsartan y simvastatina.
JP2011063518A (ja) * 2009-09-15 2011-03-31 Tohoku Univ Arb及び/又はグリタゾン系血糖降下物質を含有するoatp−r遺伝子発現増強組成物
WO2012016969A1 (en) 2010-08-03 2012-02-09 Novartis Ag Highly crystalline valsartan
CN103012301B (zh) * 2013-01-05 2015-06-17 江苏施美康药业股份有限公司 缬沙坦甲酯碱金属盐及其制备方法
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443983B1 (de) * 1990-02-19 1996-02-28 Ciba-Geigy Ag Acylverbindungen
KR19980703647A (ko) * 1995-04-07 1998-12-05 베르너발데크 베나제프릴 또는 베나제프릴라트 및 발사르탄을 함유하는조성물
ES2099031B1 (es) 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
EP0968434A2 (en) * 1997-02-28 2000-01-05 Burstein Laboratories, Inc. Laboratory in a disk
US6641886B1 (en) * 1999-03-23 2003-11-04 Flexplay Technologies, Inc. Directory read inhibitor for optical storage media
JP2001155346A (ja) * 1999-11-26 2001-06-08 Toshiba Corp 情報記録媒体、情報記録装置、情報記録方法、情報再生装置、情報再生方法
IL152411A0 (en) 2000-04-24 2003-05-29 Teva Pharma Zolpidem hemitartrate
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
CZ303389B6 (cs) 2000-07-19 2012-08-29 Novartis Ag Sul valsartanu a farmaceutický prípravek obsahující tuto sul
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan

Also Published As

Publication number Publication date
WO2003066606A1 (en) 2003-08-14
CA2776902A1 (en) 2003-08-14
US20030171414A1 (en) 2003-09-11
CN100548993C (zh) 2009-10-14
PL370481A1 (en) 2005-05-30
CN101633646B (zh) 2012-08-29
KR20040081178A (ko) 2004-09-20
US20050101652A1 (en) 2005-05-12
US6869970B2 (en) 2005-03-22
RU2004126862A (ru) 2005-06-27
NO20043660L (no) 2004-10-12
JP2005517696A (ja) 2005-06-16
CA2474424C (en) 2013-03-26
AU2003214054B2 (en) 2007-08-16
AU2003214054A1 (en) 2003-09-02
MXPA04007525A (es) 2004-11-10
US8058301B2 (en) 2011-11-15
HK1139681A1 (en) 2010-09-24
KR20110101257A (ko) 2011-09-15
CA2474424A1 (en) 2003-08-14
JP5303370B2 (ja) 2013-10-02
US8329919B2 (en) 2012-12-11
JP4895475B2 (ja) 2012-03-14
NO328155B1 (no) 2009-12-21
KR20120054667A (ko) 2012-05-30
CN101633646A (zh) 2010-01-27
EP1474402A1 (en) 2004-11-10
NZ534560A (en) 2007-05-31
ZA200405698B (en) 2006-05-31
BR0307442A (pt) 2005-01-04
JP2009235086A (ja) 2009-10-15
CN1628106A (zh) 2005-06-15
US20120022268A1 (en) 2012-01-26
ECSP045221A (es) 2004-09-28

Similar Documents

Publication Publication Date Title
NO20050542L (no) Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin
AR112669A2 (es) Compuestos inhibidores del cotransportador de sodio y glucosa 2 y compuestos útiles para su preparación
PL2185510T3 (pl) Nowe sole bazedoksyfenu
GB2395946B (en) Method for the production of sodium chloride from seawater
DK1466912T3 (da) 2-acylaminothiazolderivat eller salt deraf
IL150511A0 (en) Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
AR043266A2 (es) Forma cristalina de la sal de adicion de acido monometansulfonico de un derivado de n-fenil-2-pirimidinamina
NO20055730D0 (no) Forbedret produksjon av rosuvastatin kalsiumsalt
CO5670355A2 (es) Forma cristalina de sal de calcio de acido bis [(e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metilsulfonil)amino]pirimidin-5-il](3r,5s)-3,5-dihidroxihept-6-enoico
GB2393888B (en) Water supply arrangement for flowerpot or the like
ECSP045221A (es) Sales de valsartan
JP2009536652A5 (cg-RX-API-DMAC7.html)
AR046319A1 (es) Sal de tiotropio y composiciones farmaceuticas que la contienen.
IS7969A (is) Pýridínafleiður sem eru gagnlegar við að hamla natríum/kalsíumskiptikerfi
PT1036783E (pt) Sal de calcio hidratado cristalino de simvastatina sob a forma de di-hidroxiacido aberto
EP1757604A4 (en) PROCESS FOR THE PRODUCTION OF SOLIFENACIN OR ITS SALT
HRP20050361A2 (en) Synthesis of thiophenecarboxylic acid esters for the production of ramelic acid salts
DE602004031744D1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
WO2005100352A8 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
AR053119A1 (es) Forma cristalina b del monohidrato de la sal monosodica del acido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1,1-difosfonico (ibandronato)
GB2394678B (en) Magnesium chloride production method from seawater
PE20081402A1 (es) Sales de timo depresores farmaceuticamente aceptables y procesos para su manufactura
ATE355255T1 (de) Auflösungshemmende mittel zur herstellung von gereinigten solen
ITMI20042231A1 (it) Cefdinir sale d'ammonio in forma cristallina
AR054131A1 (es) Hidratos de sales alcalino-terreas de irbesartan y su preparacion

Legal Events

Date Code Title Description
FC Application refused